Vin Dang
Optometrist · Bakersfield, CANPI 1053503979
Payments from drug & device makers
Across 665 payments — averaging $490.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$74K
- Glaukos Corporation$43K
- Sun Pharmaceutical Industries Inc.$42K
- AbbVie$35K
- Tarsus Pharmaceuticals, Inc.$26K
- Sight Sciences, Inc.$23K
- plus $83K from 22 others
What the payments were for
- Consulting fees$80,91229%
- Speaking & faculty fees$145,74951%
- Travel & lodging$39,93814%
- Food & beverage$16,8806%
- Education$700%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 108 | $73,782 |
| Glaukos Corporation | 27 | $43,476 |
| Sun Pharmaceutical Industries Inc. | 82 | $41,732 |
| AbbVie(2 entities) | 77 | $35,038 |
| Tarsus Pharmaceuticals, Inc. | 30 | $25,772 |
| Sight Sciences, Inc. | 33 | $23,268 |
| Oyster Point Pharma, Inc. | 44 | $17,628 |
| Novartis | 49 | $12,095 |
| Biotissue Holdings Inc. | 28 | $10,294 |
| Dompe US, Inc. | 29 | $8,829 |
| Kala Pharmaceuticals, Inc. | 16 | $6,857 |
| Carl Zeiss Meditec, Inc. | 8 | $6,052 |
| Harrow Eye, LLC | 18 | $3,930 |
| Eyevance Pharmaceuticals LLC | 34 | $3,864 |
| Shire North American Group Inc | 13 | $3,813 |
| Johnson & Johnson Surgical Vision, Inc. | 6 | $2,584 |
| Amgen(2 entities) | 8 | $2,312 |
| Alcon | 12 | $1,340 |
| Thea Pharma Inc. | 5 | $1,169 |
| Aerie Pharmaceuticals, Inc. | 7 | $726 |
| Ocular Therapeutix, Inc. | 6 | $570 |
| Carl Zeiss Meditec USA, Inc. | 7 | $559 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $284 |
| Johnson & Johnson Vision Care, Inc. | 3 | $152 |
| Mallinckrodt Hospital Products Inc. | 2 | $140 |
| Coopervision Inc. | 3 | $95 |
| Quidel Corporation | 1 | $33 |
| Sanofi | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIIDRA$63,248
- MIEBO$51,663
- CEQUA$40,278
- VUITY$26,018
- XDEMVY$22,062
- TYRVAYA$16,924
- TearCare$10,915
- Oxervate$8,195
- OMNI$8,000
- EYSUVIS$6,723
- CIRRUS HD-OCT$5,814
- FORUM$4,750
- CLARUS$4,150
- Prokera$3,760
- OMNI(R) SURGICAL SYSTEM (US)$3,750
- VEVYE$3,600
- Flarex$3,487
- IOLMaster 500$3,000
- One Series Ultra IOL Delivery System$2,500
- TEPEZZA$2,145
How this compares
$326,425 in reported general payments places this provider in the 95th percentile of 6,778 optometrist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 53 | $96,484 |
| XiidraLifitegrast | 81 | $93,247 |
| RestasisCyclosporine | 78 | $91,190 |
| CequaCyclosporine | 74 | $74,690 |
| TyrvayaVarenicline Tartrate | 84 | $74,684 |
| MieboPerfluorohexyloctane/Pf | 48 | $57,070 |
| Cyclosporine | 98 | $43,467 |
| VevyeCyclosporine | 36 | $27,570 |
| VyzultaLatanoprostene Bunod | 15 | $10,681 |
| FlarexFluorometholone Acetate | 80 | $10,060 |
| ZioptanTafluprost/Pf | 19 | $8,835 |
| Lotemax SmLoteprednol Etabonate | 16 | $3,889 |
| Fluorometholone | 22 | $1,603 |
| Prednisolone Acetate | 37 | $1,335 |
| MoxifloxacinMoxifloxacin Hcl | 40 | $792 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $73,782 | $160,999144 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $25,772 | $96,48453 claims |
| AbbVieRestasis | $35,038 | $91,19078 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $41,732 | $74,69074 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $17,628 | $74,68484 claims |
| Harrow Eye, LLCVevye | $3,930 | $27,57036 claims |
| Eyevance Pharmaceuticals LLCFlarex | $3,864 | $10,06080 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm | $284 | $3,88916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,778 optometrist providers in California.
Other optometrist in Bakersfield
- Meng LinBerkeley$6.9M
- Steve YoelinNewport Beach$6.1M
- Matthew GellerSpring Valley$3.5M
- David Kasanoffla Mesa$1M
- Colton HeinrichFullerton$987K
- Elsa PaoOakland$910K
- Keith WanSan Diego$887K
- Selena ChanSan Francisco$677K
- Melissa EricksonDavis$522K
- Omid KhodaiLake Forest$499K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.